{
    "eid": "2-s2.0-85122666458",
    "title": "SARS-CoV-2 omicron variant: Could it be another threat?",
    "cover-date": "2022-04-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Virology",
            "@code": "2406",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Balamurugan Shanmugaraj",
        "Ashwini Malla",
        "Narach Khorattanakulchai",
        "Waranyoo Phoolcharoen"
    ],
    "citedby-count": 14,
    "ref-count": 26,
    "ref-list": [
        "Genome-wide analysis of SARS-CoV-2 virus strains circulating worldwide implicates heterogeneity",
        "Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics",
        "Impact of the Delta variant on vaccine efficacy and response strategies",
        "Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert!",
        "Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear",
        "Omicron variant genome evolution and phylogenetics",
        "Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity",
        "Spike mutation D614G alters SARS-CoV-2 fitness",
        "Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera",
        "The global epidemic of SARS-CoV-2 variants and their mutational immune escape",
        "Detection of highly muted coronavirus variant Omicron (B.1.1.529) is triggering the alarm for South Asian countries: associated risk factors and preventive actions",
        "Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern and its global perspective",
        "Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine",
        "Protection of BNT162b2 vaccine booster against Covid-19 in Israel",
        "SARS-CoV-2 variants and ending the COVID-19 pandemic"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "123658611",
            "affilname": "Ltd",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123658611",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "National Vaccine Institute, Thailand and Baiya Phytopharm Co., Ltd.",
        "Chulalongkorn University"
    ]
}